{"id":"placebo-cp-690-550","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Upper respiratory tract infection"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"15-25","effect":"Nasopharyngitis"},{"rate":"10-20","effect":"Elevated cholesterol"},{"rate":"5-10","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CP-690,550 (tofacitinib) selectively inhibits JAK1 and JAK3 kinases, which are critical for cytokine signaling in T cells and other immune cells. By blocking these kinases, the drug suppresses the production of pro-inflammatory cytokines and reduces pathogenic T cell activation, thereby dampening autoimmune and inflammatory responses.","oneSentence":"CP-690,550 is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:25.443Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"},{"name":"Polyarticular course juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT03000439","phase":"PHASE3","title":"A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-05-10","conditions":"Arthritis Juvenile Idiopathic","enrollment":100},{"nctId":"NCT01246583","phase":"PHASE2","title":"CP-690-550 Ointment For Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-02-16","conditions":"Psoriasis","enrollment":71},{"nctId":"NCT01743677","phase":"PHASE1","title":"CP-690,550 Thorough QTc Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-10-26","conditions":"Healthy","enrollment":60},{"nctId":"NCT01815424","phase":"PHASE3","title":"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12","conditions":"Psoriasis","enrollment":266},{"nctId":"NCT01458574","phase":"PHASE3","title":"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07-20","conditions":"Ulcerative Colitis","enrollment":593},{"nctId":"NCT01465763","phase":"PHASE3","title":"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-04","conditions":"Ulcerative Colitis","enrollment":614},{"nctId":"NCT01458951","phase":"PHASE3","title":"A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06","conditions":"Ulcerative Colitis","enrollment":547},{"nctId":"NCT02001181","phase":"PHASE2","title":"Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12","conditions":"Dermatitis, Atopic","enrollment":69},{"nctId":"NCT00787202","phase":"PHASE2","title":"A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-12","conditions":"Ulcerative Colitis","enrollment":195},{"nctId":"NCT00550446","phase":"PHASE2","title":"A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-09","conditions":"Arthritis, Rheumatoid","enrollment":386},{"nctId":"NCT01059864","phase":"PHASE2","title":"Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-02","conditions":"Rheumatoid Arthritis","enrollment":111}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo/CP-690,550","genericName":"Placebo/CP-690,550","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CP-690,550 is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory immune responses. Used for Rheumatoid arthritis, Ulcerative colitis, Psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}